Restore the core! Selinexor (ATG-010), a first-in-class drug for multiple myeloma, to be launched in Hainan Free Trade Port

Release date: 2021-01-11
Author:
View PDF

In order to further enhance medication safety and meet urgent clinical needs of patients, Antengene Corporation limited (“Antengene”, SEHK: 6996.HK) and Hainan Chengmei Medicine Corporation limited (“Chengmei Medicine”) jointly held the “Restore of core – Special Permission to Import Selinexor in Boao Lecheng Pilot Zone for Multiple Myeloma Press Conference” in Haikou on January 9, 2021. Li Yunda, Deputy Director of the Hainan Medical Products Administration (MPA), Fu Zhu, Deputy Director of the Boao Lecheng International Medical Tourism Pilot Zone, Li Ping, L2 Research Fellow of Healthcare Industry International Cooperation Bureau, Hainan Health Commission, Ma Jun, Director of the Harbin Institute of Hematology & Oncology and Chief Supervisor of Supervisory Committee at the Chinese Society of Clinical Oncology (CSCO), Jay Mei, Founder, Chairman and CEO of Antengene, and Lin Shiquan, Chairman of Chengmei Medicine, Executive Director General of Hainan Cancer Hospital and General Manager of Boao Super Hospital, Yao Lijun, General Manager of Hainan Chengmei Medicine, attended the conference.

image.png

conference scene



Under the effective implementation of the Overall Plan for Construction of Hainan Free Trade Port, Antengene and Chengmei Medicine will jointly introduce selinexor, a drug for treatment of multiple myeloma, in Hainan Boao Lecheng International Medical Tourism Pilot Zone to build a convenient and efficient medication channel for patients in China. With the issuance and implementation of the Interim Measures for the Administration of the Use of Imported Drugs Urgently Needed for Clinical Use in the Hainan Boao Lecheng International Medical Tourism Pioneer Zone, Selinexor will become the first selective inhibitor for nuclear export (SINE) to be used by Chinese multiple myeloma patients simultaneously with other patients across the world.


As the second major hematological malignancy, multiple myeloma can hardly be cured by the currently limited therapeutic options. In China, the patients with multiple myeloma, who have received the treatment of multiple drugs but still relapse, are facing the clinical dilemma of no other drugs available. Selinexor (ATG-010) is the first-in-class clinically validated SINE, and its two major indications on hematological malignancies – multiple myeloma and diffuse large B-cell lymphoma (DLBCL), have been approved successively within one year. As the world’s first and only SINE for the two major indications, Selinexor’s five therapeutic options have been included in the NCCN guidelines. In December last year, FDA once again approved selinexor for frontline patients with multiple myeloma, which further expanded the prospect of selinexor’s clinical application. Thanks to the preferential policies issued by Hainan Free Trade Port, the Chinese patients with multiple myeloma are able to use the world-leading innovative therapy simultaneously with other patients across the world.


 image.png


Fu Zhu, Deputy Director of the Boao Lecheng International Medical Tourism Pilot Zone, said that: “Lecheng Pilot Zone welcomes leading international pharmaceutical enterprises like Antengene to introduce the drugs urgently needed by domestic patients into Hainan, so that they can get international medical services and advanced drugs as soon as possible. We expect to maintain a long-term partnership with Antengene to import more new drugs approved overseas simultaneously in Hainan, and benefit Chinese patients with more cutting-edge international drugs and medical devices in a timely manner.”


 image.png


Li Yunda, Deputy Director of the Hainan Medical Products Administration, said that: “As the only ‘special zone of medical services’ in China, Lecheng Pilot Zone has gradually set up a diagnosis and treatment specialty with distinctive advantages, and preliminarily achieved the ‘triple synchronization’ of healthcare technology, drugs and medical devices with the international level. We sincerely expect that Hainan First Investment Group, Hainan Chengmei Medicine and excellent enterprises like Antengene, who have outstanding sense of social responsibilities, will jointly introduce more new drugs worldwide to benefit the Chinese patients with timely and first-class healthcare services, and make new contributions to the development of Hainan Free Trade Port.”


 image.png


Ma Jun, Director of the Harbin Institute of Hematology & Oncology and Chief Supervisor of Supervisory Committee at the Chinese Society of Clinical Oncology (CSCO), said that: “The practice of saving more patients through introducing innovative drugs conforms to the principle of ‘Life First’ advocated by our country. Based on the new policies, the patients in China can save and extend their lives by the innovative drugs introduced without waiting for their official approvals for launching in China. As selinexor is an oral drug, the patients can use it conveniently with high dependence. Through the current joint efforts, we are able to bring a faster, better and more timely new therapeutic option to greatly improve the accessibility for the Chinese patients. Thanks to the preferential medical policies issued by Boao Lecheng Pilot Zone, we believe that selinexor will greatly benefit the vast number of patients with cancers. As ‘medicine is inseparable from pharmacy’, the clinicians will also have more useful tools, and gradually align with the international standards in the choice of therapeutic options.”


 image.png


Yao Hongxia, Director of Hematology Commission of Hainan Medical Association and Initial President of Hainan Society of Hematologists, said that: “As a medical practitioner working in the Pilot Zone of International Medical Tourism, I feel very honored to be able to participate in and witness the import of more novel drugs in China. Thanks to the great support from the State Council and Hainan Provincial Government, the preferential polices issued by Boao Lecheng have given me an opportunity to know the information about these new drugs earlierly, and I am also willing to contribute my own strength to enable the Chinese patients with hematological diseases to receive effective treatment in a timely manner. As a new mechanism of action, Selinexor’s indications for MM and DLBCL approved in the US have shown excellent efficacy. I believe that the import of selinexor is a great benefit for Chinese patients, and I am looking forward to seeing its efficacy in the Chinese population.”


 image.png


Lin Shiquan, Chairman of Chengmei Medicine, Executive Director General of Hainan Cancer Hospital and General Manager of Boao Super Hospital, said that: “The official release of the Overall Plan for Construction of Hainan Free Trade Port is a further breakthrough in the pilot program for global innovative therapies in Hainan. As the first drug approved by FDA for the treatment of multiple myeloma and diffuse large B-cell lymphoma, the introduction of selinexor is another successful practice of preferential policies in the Pilot Zone. Chengmei Medicine will work with leading domestic and overseas biopharmaceutical company like Antengene to continuously introduce more international innovative drugs and medical devices to benefit the Chinese patients.”


 image.png


Jay Mei, Founder, President and CEO of Antengene, said that: “The introduction of selinexor into Hainan Free Trade Port as a drug urgently needed in clinical practice means that the patients in China will share this advanced therapy with other patients across the world. As the first-in-class SINE compound, Selinexor will be used in clinical treatment for more diversified and broader groups. Based on the mission of ‘Treating Patients beyond Borders’, Antengene will enhance independent R&D and clinical study capabilities, and focus on the diseases with high incidences in China and APAC to further explore the potential of our products. In addition, Antengene will work closely with the governments, hospitals and relevant social sectors to jointly create a diversified and open pharmaceutical innovation ecosystem, and apply the cutting-edge innovative therapies to Chinese patients as soon as possible.”


 image.png

signing ceremony



At the press conference, the “Signing ceremony of special permission to import selinexor in Boao Lecheng Pilot Zone for Multiple Myeloma” was held simultaneously. Dr. Jay Mei, Chairman of Antengene, and Ms. Yao Lijun, General Manager of Hainan Chengmei Medicine, signed a strategic cooperation agreement.


In the future, Antengene will provide the multiple myeloma patients in urgent needs with a convenient healthcare channel and an affordable therapeutic approach based on the preferential policies issued by the Free Trade Port as well as the medical and technical resources in the Lecheng Pilot Zone. Through standardized project management, systematic patient education and multi-channel training model, Antengene will ensure the safe and reliable medication for patients.


About Selinexor (ATG-010, XPOVIO®)


Selinexor (ATG-010, XPOVIO®) is the world’s first and only oral SINE compound developed by Karyopharm Therapeutics Inc. (NASDAQ: KPTI). Through the exclusive authorization by Karyopharm, Antengene has acquired the exclusive development and commercialization rights and benefits of Selinexor in several APAC markets including Greater China, South Korea, Australia, New Zealand and ASEAN.


In July 2019, the U.S. Food and Drug Administration (FDA) approved the therapy of Selinexor combined with low-dose dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma (rrMM). In June 2020, FDA once again approved Selinexor as a single-agent oral therapy for the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma (rrDLBCL). In addition, a marketing authorization application (MAA) of Selinexor has been submitted to the European Medicines Agency (EMA) for conditional approval of Selinexor for rrMM. In December 2020, FDA approved the supplemental New Drug Application (sNDA) for extended indications of Selinexor for the multiple myeloma patients who have previously received at least first-line therapies. Selinexor is currently the first and only oral SINE compound approved by FDA for the treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition, Selinexor has undergone multiple mid-stage and late-stage clinical trials for multiple solid tumor indications, including liposarcoma and endometrial cancer. In November 2020, Karyopharm, a partner of Antengene, reported the positive data of the Phase III SEAL trial at the 2020 Annual Conference of Connective Tissue Oncology Society (CTOS 2020). SEAL is a randomized, double-blind, placebo-controlled crossover trial designed to compare the efficacy of oral single-agent Selinexor with placebo in patients with liposarcoma. In addition, Karyopharm recently announced that the phase III SIENDO trial of Selinexor for the treatment of patients with endometrial cancer has completed the planned interim inefficacy analysis, and the Data Security Monitoring Board (DSMB) recommended that the SIENDO trial can proceed as planned with no modification. The primary data and results of the SIENDO trial are expected to be announced in the second half of 2021.


Antengene is currently implementing a phase II registrational clinical trial of Selinexor for relapsed and refractory multiple myeloma (code name: MARCH) and a phase II registrational clinical trial of Selinexor for relapsed and refractory diffuse large B-cell lymphoma (code name: SEARCH) in China. At the same time, for the tumors with high incidences in APAC, Antengene has launched the clinical trial of Selinexor for the treatment of peripheral T-cell lymphoma, NK/T cell lymphoma (code name: TOUCH) and KRAS mutant non-small cell lung cancer (code name: TRUMP).


About Antengene


Antengene Corporation Limited (“Antengene” for short, SEHK: 6996.HK), a clinical-stage biopharmaceutical company in the Asia-Pacific region focusing on innovative anti-tumor drugs, aims to provide the most cutting-edge and innovative anti-tumor therapies for the patients in China, in the Asia-Pacific region, or even across the world. Since the date of establishment, Antengene has set up a diversified product pipeline covering 12 clinical and preclinical innovative drugs, and obtained 11 approvals for clinical trials in the Asia-Pacific region. Based on the vision of “Treating Patients beyond Borders”, Antengene strives to meet the unmet clinical needs of patients in Asia-Pacific region and even across the world through specialized studies and marketization for the first-in-class/best-in-class therapies.


Forward-looking Statement


The forward-looking statements made in this article only relate to the events or information as of the date when the statement is made. Unless otherwise stipulated by the laws, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear. Please read this article carefully, and understand that our actual results or performances in the future may differ materially from the expectations. The statements or references in this article about the intentions of any directors or the company are made on the date of this article, and any such intentions may change due to further progresses.



Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Learn more

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Learn more

Antengene to Present at Upcoming Industry Conferences

Learn more

Antengene’s ATG-101 Receives the NMPA’s IND Approval for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Learn more

Study highlights Antengene's complementary focus on diseases with a higher prevalence in China

Learn more

Antengene announces XPOVIO approved by Australia for multiple myeloma

Learn more

Singapore Health Sciences Authority approves Antengene’s Xpovio to treat R/R MM & R/R DLBCL in three indications

Learn more

Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma

Learn more

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update

Learn more

Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor

Learn more

Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Learn more

Antengene Appoints Bo Shan as Chief Scientific Officer

Learn more

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma

Learn more

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Learn more

Celgene and Antengene Corporation Announced Long-term Collaboration and Celgene has Become Shareholder of Antengene

Learn more

Antengene announces China manufacturing plant in Shaoxing, China

Learn more

Antengene Corporation Attend Qiming Venture Partners CEO Summit

Learn more

Antengene Corporation Secures $21M in Series A Financing Round Led by Qiming Venture Partners

Learn more

Antengene Corporation Attend the 20th Annual CSCO Meeting

Learn more

Antengene Corporation attended Drug Development Case Study Workshop held by CFDA

Learn more

Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea

Learn more

Antengene Corporation Announces TFDA Approval of IND Application for a Phase II Study of ATG-008, a Next Generation mTOR Inhibitor, in Patients with Late-stage Hepatocellular Carcinoma (HCC)

Learn more

Dr. Yijun Yang and Dr. Bo Shan joined Antengene Corporation

Learn more

Antengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia

Learn more

International Torch Study (ATG-008-HCC-001) Investigator Meeting held by Antengene

Learn more

ATG-008, China’s first TORC1/2 dual-targeted inhibitor of the new generation, has obtained IND approval

Learn more

Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor

Learn more

Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma

Learn more

Antengene and WuXi STA announced a strategic cooperation in process R&D and manufacturing

Learn more

Antengene launches patient enrollment for TORC1/2 dual-targeted inhibitor ATG-008 in Taiwan

Learn more

Antengene Presents a Series of Reports on TORC1/TORC2 Dual-Targeted Inhibitor ATG-008 at the 21st Annual Meeting of Chinese Society of Clinical Oncology

Learn more

Karyopharm,Antengene Corporation’s Strategic Partner, Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor (ATG-010)as a Treatment for Patients with Penta-Refractory Multiple Myeloma

Learn more

Antengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese Society of Clinical Oncology

Learn more

Antengene Corporation won the Project Support of “the 13th Five- Year National Major New Drug Development Project”

Learn more

Antengene Corporation Raises $120 Million in Series B Financing

Learn more

Antengene Team Standing Out as a Leader in Innovation and Entrepreneurship

Learn more

ATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma

Learn more

Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute

Learn more

Strong alliance for finding a new treatment of liver cancer: Antengene cooperates with Junshi Biosciences to conduct clinical research on the combination therapy of ATG-008 and Toripalimab to treat advanced liver cancer

Learn more

Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Learn more

Latest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export

Learn more

Take the crown! — Antengene was awarded the first prize in the 8th China Innovation& Entrepreneurship Competition

Learn more

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Learn more

News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China

Learn more

Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer

Learn more

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

Learn more

Antengene Presented a Keynote Speech at J.P. Morgan Conference

Learn more

News Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved

Learn more

Novel oral medication for diffuse large B-cell lymphoma! Another indication of XPOVIO®, a first-in-class nuclear export inhibitor, is expected to achieve accelerated approval

Learn more

Phase 3 Clinical Study of Novel Selective Inhibitor of Nuclear Export Selinexor with New Combination Therapy for Multiple Myeloma Meets Primary Endpoint

Learn more

Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Learn more

Clinical trial of Antengene’s ATG-008 in combination with Junshi Biosciences’ Toripalimab for treatment of advanced solid tumors and hepatocellular carcinoma officially initiated

Learn more

Phase 2 clinical trial of ATG-008 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Learn more

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma

Learn more

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

Learn more

Antengene Announces First Patient Dosed in China Registration Trial of ATG-010 (selinexor) for Relapsed or Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Learn more

Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

Learn more

Antengene Doses First Patient with ATG-008, a mTOR1/2 Dual-targeted Inhibitor, for Advanced Solid Tumors and Hepatocellular Carcinoma of the Clinical Trial with Junshi Biosciences’ Toripalimab

Learn more

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

Learn more

Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

Learn more

Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

Learn more

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Learn more

Australian Therapeutic Goods Administration (TGA) Approves the First Phase I Trial of ATG-017 (ERK 1/2 inhibitor) for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

Learn more

Antengene Announces IND Approval by NMPA to Initiate a Phase II Clinical Trial of ATG-008 for the Treatment of Advanced Solid Tumors with Specific Genetic Alterations

Learn more

Antengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Learn more

Antengene Announces First Patient Dosing in a Phase I Trial of ATG-017 in Advanced Solid Tumors and Hematological Malignancies in Australia

Learn more

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

Learn more

Antengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

Learn more

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

Learn more

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

Learn more

Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

Learn more

Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

Learn more

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

Learn more

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

Learn more

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

Learn more

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

Learn more

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

Learn more

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

Learn more

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

Learn more

Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference

Learn more

Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

Learn more

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

Learn more

Antengene Partners with SAP to Implement an Automated Digital Enterprise Management System

Learn more

Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Learn more

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA

Learn more

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

Learn more

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

Learn more

Antengene Included in the Shenzhen-Hong Kong Stock Connect

Learn more

Antengene Announces Financial Results for Full Year 2020

Learn more

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Learn more

Antengene Appoints Bo Shan as Chief Scientific Officer

Learn more

Antengene Appoints Kevin Lynch as Chief Medical Officer

Learn more

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

Learn more

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

Learn more

Treatment with Selinexor in Advanced Liposarcoma Demonstrates Clinically Important Reduction in Pain with Improved HRQoL Outcomes

Learn more

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Learn more

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Learn more

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

Learn more

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

Learn more

Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China

Learn more

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

Learn more

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Learn more

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

Learn more

Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome

Learn more

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

Learn more

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

Learn more

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Learn more

Antengene’s Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

Learn more

Antengene Provides an Update on Its Latest Developments

Learn more

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Learn more

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies

Learn more

Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Learn more

Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets

Learn more

Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Learn more

Antengene Selected as a Constituent of the FTSE Global Equity Index Series

Learn more

Antengene Announces Up to HK$100 million Share Repurchase Program

Learn more

Antengene Announces IND Submitted to U.S. FDA for Its PD-L1/4-1BB Bispecific Antibody ATG-101 in Solid Tumors and Non-Hodgkin Lymphoma

Learn more

Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021

Learn more

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

Learn more

Antengene to Host its First R&D Days on November 16 and November 18, 2021

Learn more

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

Learn more

Antengene Announces IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Learn more

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

Learn more

Antengene Announces XPOVIO® Regulatory Approval in Singapore

Learn more

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

Learn more

Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference

Learn more

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Learn more

Antengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Learn more

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

Learn more

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Learn more

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018

Learn more

Antengene and XtalPi Announce AI-Driven R&D Collaboration

Learn more

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

Learn more

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH)

Learn more

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Learn more

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Learn more

Antengene Announces NDA Approval by NMPA for XPOVIO®, China’s First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

Learn more

Antengene Included in the MSCI Global Small Cap Indexes – MSCI China Index Constituent Stocks

Learn more

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

Learn more

Antengene to Release Preliminary Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of Peripheral T-Cell Lymphoma and NKT-Cell Lymphoma at the 2021

Learn more

Antengene Announces IND Approval in China for a Phase I II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

Learn more

Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L14-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Learn more

Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma

Learn more

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

Learn more

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101

Learn more

Antengene Announces Research Collaboration with Celularity

Learn more

“Research collaboration and introduction of new drugs will continue in South Korea, regarded as an attractive market”

Learn more

Domestic biopharmaceutical companies will have strong presence globally

Learn more

Antengene to Participate in Three Upcoming Investor Conferences in May&June

Learn more

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

Learn more

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Learn more

Antengene Announces Commercial Availability of XPOVIO® (Selinexor) Prescribed for the First Time Across Mainland China

Learn more

Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Learn more

Antengene Announces First Patient Dosed in the Phase I II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Learn more

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Learn more

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Learn more

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Learn more

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

Learn more

Privacy Notice

Privacy Notice

Last updated: July 15, 2022

This Privacy Notice describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service, and tells You about Your privacy rights and how the law protects You.

We use Your Personal data to provide and improve the Service. By using the Service, You agree to the collection and use of information in accordance with this Privacy Notice. If You do not agree to these terms, You are not authorized to use Our Service.

1. Definitions

The following definitions shall have the same meaning regardless of whether they appear in singular or in plural.

For the purposes of this Privacy Notice:

Affiliate means with respect to a specified person or entity, any other person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified person or entity, and the term “control” (including the terms controlling, controlled by and under common control with) means the possession, direct or indirect, of (i) the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise or (ii) 50% or more of the issued share capital of an entity.

Antengene (referred to as either "Antengene", "We", "Us" or "Our" in this Agreement) refers to Antengene Corporation Limited and its Affiliates.

Cookies are small files that are placed on Your computer, mobile device or any other device by a website, containing the details of Your browsing history on that website among its many uses.

Device means any device that can access the Service such as a computer, a cellphone or a digital tablet.

Personal Information is any information that relates to an identified individual or can be used to identify a person, either directly or indirectly (e.g. by combining different sets of indirect indentifiers).

Service refers to the Website and its mobile applications.

Service Provider means any third party that processes Personal Information under the instructions of Antengene or to which Antengene discloses information for use on Antengene’s behalf.

Usage Data refers to data collected automatically, either generated by the use of the Service or from the Service infrastructure itself (for example, the duration of a page visit).

Website refers to Antengene Website, accessible from antengene.com

You means the individual accessing or using the Service, or the legal entity on behalf of which such individual is accessing or using the Service, as applicable.

2. Information We Collect

2.1 Personal Information

While using Our Service, We may ask You to provide Us with certain personally identifiable information that can be used to contact or identify You. Personally identifiable information may include, but is not limited to Your name, postal address, telephone number, email address, date of birth, identification numbers, and health, financial and professional information.

2.2 Usage Data

Usage Data is collected automatically when using the Service.

a) Usage Data may include information such as Your Device's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Service that You visit, the time and date of Your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

b) When You access the Service by or through a mobile device, We may collect certain information automatically, including, but not limited to, the type of mobile device You use, Your mobile device unique ID, the IP address of Your mobile device, Your mobile operating system, the type of mobile Internet browser You use, unique device identifiers and other diagnostic data.

c) We may also collect information that Your browser sends whenever You visit our Service or when You access the Service by or through a mobile device.

2.3 Tracking Technologies and Cookies

We use Cookies and similar tracking technologies to track the activity on Our Service and store certain information. Tracking technologies used are beacons, tags, and scripts to collect and track information and to improve and analyze Our Service. The technologies We use may include:

a) Cookies or Browser Cookies. A cookie is a small file placed on Your Device. You can instruct Your browser to refuse all Cookies or to indicate when a Cookie is being sent. However, if You do not accept Cookies, You may not be able to use some parts of our Service. Unless you have adjusted Your browser setting so that it will refuse Cookies, our Service may use Cookies.

b) Flash Cookies. Certain features of our Service may use local stored objects (or Flash Cookies) to collect and store information about Your preferences or Your activity on our Service. Flash Cookies are not managed by the same browser settings as those used for Browser Cookies.

c) Web Beacons. Certain sections of our Service and our emails may contain small electronic files known as web beacons (also referred to as clear gifs, pixel tags, and single-pixel gifs) that permit Antengene, for example, to count users who have visited those pages or opened an email and for other related website statistics (for example, recording the popularity of a certain section and verifying system and server integrity).

3. Use of Your Personal Information

3.1 Antengene may use Personal Information for the following purposes:

a) To provide and maintain our Service, including to monitor the usage of our Service, site administration and maintenance, and security improvements.

b) To provide You with general health information (such as information on certain health conditions) as well as information about Our products and services;.

c) To respond to Your requests: To attend and manage Your requests, inquiries, or applications to Us.

d) For business transfers: We may use Your information to evaluate or conduct a merger, divestiture, restructuring, reorganization, dissolution, or other sale or transfer of some or all of Our assets, whether as a going concern or as part of bankruptcy, liquidation, or similar proceeding, in which Personal Information held by Us about our Service users is among the assets transferred.

e) For other purposes: We may use Your information for other purposes where it is necessary for Our legitimate interest as a company, including but not limited to research and development, regulatory reporting, contract management, fulfillment, analytics, fraud prevention, corporate governance, reporting, legal compliance, data analysis, identifying usage trends, determining the effectiveness of our promotional campaigns and to evaluate and improve our Service, products, services, marketing and your experience.

3.2 We will not sell, share, or otherwise distribute Your Personal Information to third parties except as provided in this Privacy Notice. We may share Your Personal Information in the following situations:

a) With Service Providers: We may share Your Personal Information with Service Providers for further processing, such as to monitor and analyze the use of our Service, or to contact You. These Service Providers have contracted with Us to only use the Personal Information for the purpose(s) for which the data were originally collected or may otherwise be lawfully processed, not to sell Your Personal Information to other third parties, and not to disclose it to other third parties except as may be required by law, as permitted by Us or as stated in this Privacy Policy.

b) For business transfers: We may share or transfer Your Personal Information in connection with, or during negotiations of, any merger, sale of Antengene assets, financing, or acquisition of all or a portion of Our business to another company.

c) With Affiliates: We may share Your information with Our Affiliates, in which case we will require those Affiliates to honor this Privacy Notice.

d) With Your consent: We may disclose Your Personal Information for any other purpose with Your consent.

 

3.3 Retention of Your Personal Information

a) Antengene will retain Your Personal Information only for as long as is necessary for the purposes set out in this Privacy Notice. We will retain and use Your Personal Information to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies.

b) Antengene will also retain Usage Data for internal analysis purposes. Usage Data is generally retained for a shorter period of time, except when this data is used to strengthen the security or to improve the functionality of Our Service, or We are legally obligated to retain this data for longer time periods.

4. Sharing Your Personal Information

4.1 Your information, including Personal Information, is processed at Antengene's operating offices and in any other places where the parties involved in the processing are located. It means that this information may be transferred to — and maintained on — computers located outside of Your state, province, country or other governmental jurisdiction where the data protection laws may differ than those from Your jurisdiction. Therefore, by using the Service or otherwise providing information to Us, You hereby expressly consent to the transfer of Your Personal Information outside Your country or region.

4.2 If Antengene is involved in a merger, acquisition or asset sale, Your Personal Information may be transferred. We will provide notice before Your Personal Information is transferred and becomes subject to a different Privacy Notice.

4.3 Under certain circumstances, Antengene may be required to disclose Your Personal Information if required to do so by law or in response to valid requests by public authorities (e.g. a court or a government agency).

4.4 Antengene may disclose Your Personal Information in the good faith belief that such action is necessary to:

a) Comply with a legal obligation;

b) Protect and defend the rights or property of Antengene;

c) Prevent or investigate possible wrongdoing in connection with the Service;

d) Protect the personal safety of Users of the Service or the public;

e) Protect against legal liability

5. Data Security

The security of Your Personal Information is important to Us, and We use commercially reasonable administrative, technical, personnel-related, and physical security measures designed to safeguard the Personal Information in Our possession against loss, theft and unauthorized use, disclosure, or modification. But remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. We cannot guarantee its absolute security. In the event of a security incident involving Your Personal Information, as required by applicable laws, We will inform You in a timely manner and report the incident to relevant regulatory authorities.

6. Children's Privacy

We are committed to protecting the privacy of children. The Service is not intended for, or designed to attract, children under the age of 18. We do not knowingly collect personally identifiable information from anyone under the age of 18. If You are a parent or guardian and You are aware that Your child has provided Us with Personal Information, please contact Us. If We become aware that We have collected Personal Information from anyone under the age of 18 without verification of parental consent, We take steps to remove that information from Our servers.

7. Links to Other Websites

7.1 Our Service may contain links to other websites that are not operated by Us. If You click on a third-party link, You will be directed to that third party's site. We strongly advise You to review the Privacy Notice of every site You visit.

7.2 We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

8. Changes to this Privacy Notice

8.1 We may update Our Privacy Notice from time to time. We will notify You of any changes by posting the new Privacy Notice on this page.

8.2 We will let You know via email and/or a prominent notice on Our Service, prior to the change becoming effective and update the "Last updated" date at the top of this Privacy Notice.

8.3 You are advised to review this Privacy Notice periodically for any changes. Changes to this Privacy Notice are effective when they are posted on this page.

9. Contact Us

You may contact us at any time if You have questions about this Privacy Notice.  Under applicable data protection laws, You may have the right to object to or request restriction of processing of Your Personal Information and to request access to, rectification, erasure and portability of the Personal Information We hold about You, subject to certain exceptions prescribed by law.  To reach Us, please send an email to: privacy@antengene.com, and we shall endeavor to answer Your inquiry as soon as reasonably possible in compliance with applicable laws.


Terms og Use

Terms and Conditions

Last updated: July 15, 2022

Please read these Terms and Conditions carefully before using Our Service.

1. Definitions

The following definitions shall have the same meaning regardless of whether they appear in singular or in plural.

For the purposes of these Terms and Conditions:

Affiliate means with respect to a specified person or entity, any other person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified person or entity, and the term “control” (including the terms controlling, controlled by and under common control with) means the possession, direct or indirect, of (i) the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise or (ii) 50% or more of the issued share capital of an entity.

Antengene (referred to as either "Antengene", "We", "Us" or "Our" in this Agreement) refers to Antengene Corporation Limited and its Affiliates.

Device means any device that can access the Service such as a computer, a cellphone or a digital tablet.

Service refers to the Website and its mobile applications.

Terms and Conditions (also referred as "Terms") mean these Terms and Conditions that form the entire agreement between You and Antengene regarding the use of the Service.

Third-party Social Media Service means any services or content (including data, information, products or services) provided by a third-party that may be displayed, included or made available by the Service.

Website refers to Antengene Website, accessible from https://www.antengene.com/

You means the individual accessing or using the Service, or Antengene, or other legal entity on behalf of which such individual is accessing or using the Service, as applicable.

2. Acknowledgment

2.1 These are the Terms and Conditions governing the use of this Service and the agreement that operates between You and Antengene. These Terms and Conditions set out the rights and obligations of all users regarding the use of the Service.

2.2 Your access to and use of the Service is conditioned on Your acceptance of and compliance with these Terms and Conditions. These Terms and Conditions apply to all visitors, users and others who access or use the Service. If You disagree with any part of these Terms and Conditions then You may not access the Service.

2.3 By accessing or using the Service You represent and warrant that (1) You have the legal capacity and You agree to be bound by these Terms and Conditions; (2) You are not a minor in the jurisdiction in which You reside; (3) You will not access or use the Service through automated or non-human means, whether through a bot, script, or otherwise; (4) You will not access or use the Service for any illegal or unauthorized purposes; and (5) Your use of the Service will not violate any applicable law or regulation.

2.4 Your access to and use of the Service is also conditioned on Your acceptance of and compliance with the Privacy Policy of Antengene. Our Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your personal information when You use the Service and tells You about Your privacy rights and how the law protects You. Please read Our Privacy Policy carefully before using Our Service.

3. Forward Looking Statement

3.1 The Service may contain forward-looking statements regarding Antengene’s future operating or financial performance, business plans and prospects, and Our expectations regarding clinical trials, development timelines, and discussions with regulatory authorities related to drugs and drug candidates under development by Us and Our collaboration partners.

3.2 These forward-looking statements relate only to the events or information as of the date on which the statements are made. You should read these statements completely and with the understanding that Our actual future results or performance may be materially different from what We expect. In these statements of, or references to, Our intentions or those of any of Our directors or Our Company are made as of the date of those statements. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in Our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in Antengene’s Annual Report, and subsequent filings with the Hong Kong Stock Exchange.

3.3 Except as required by law, We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

4. Content and License

4.1 Antengene and its Affiliates, licensors, partners, providers, and their respective successors and assigns retain sole and exclusive ownership of all worldwide right, title and interest, including all copyrights, patent rights, trade secret rights, trademark rights, and other intellectual property and proprietary rights, in and to the Service, including all text, graphics and images, data, information, reports, software, tools, links and resources comprised in the Service or provided through the Service, as well as all technologies used by Antengene to provide and operate the Service.  Other than a limited license to use as provided below, You have and acquire no other right or license with respect to the Service or any portion or component thereof. Unless expressly authorized by applicable law or in writing by Antengene, You may not copy, reproduce, publicly perform or display, transmit, modify or otherwise create derivative works from, sell, distribute, or otherwise make unauthorized use of the Service or any portion or component thereof. Any unauthorized use of the Service or any portion or component thereof is strictly prohibited and may result in civil and/or criminal penalties. There are no implied rights or licenses granted to You under these Terms.

4.2 Subject to Your compliance with these Terms and Conditions and all applicable laws and regulations, Antengene grants You a revocable, non-exclusive, non-transferable, non-sublicensable, limited personal license to access the Service for Your lawful personal and noncommercial uses. As a condition of Your use of the Service, You agree not to: (a) take any action that imposes an unreasonable load on the Service’ infrastructure, (b) use any device, software or routine to interfere or attempt to interfere with the proper working of the Service or any activity being conducted on the Service, (c) attempt to decipher, decompile, disassemble or reverse engineer any of the software comprising or making up the Service, (d) delete or alter any material posted on the Service by Antengene or any other person or entity, or (e) frame or link to any of the materials or information available on the Service.

4.3 You acknowledge and agree that any data, questions, comments, suggestions, ideas, feedback, or other information provided by You to Antengene (“Submissions”) will be treated as non-confidential and shall become Our sole property. We shall own exclusive rights, including all intellectual property rights, and shall be entitled to the unrestricted use and dissemination of these Submissions for any lawful purpose, commercial or otherwise, without acknowledgment or compensation to You. You hereby waive all moral rights to any such Submissions, and You hereby warrant that any such Submissions are original with You or that You have the right to submit such Submissions. You agree there shall be no recourse against Us for any alleged or actual infringement or misappropriation of any proprietary right in Your Submissions. Your Submissions might be publicly accessible. Important and private information should be protected by You. Antengene is not liable for protection of privacy of email or other information transferred through the Internet or any other network that you may use.

5. Site Management

5.1 We reserve the right, but not the obligation, to: (1) monitor the Service for violations of these Terms and Conditions; (2) take appropriate legal action against anyone who, in Our sole discretion, violates the law or these Terms and Conditions, including without limitation, reporting such user to law enforcement authorities; (3) in Our sole discretion and without limitation, notice, or liability, to remove from the Service or otherwise disable all files and content that are excessive in size or are in any way burdensome to Our systems; and (4) otherwise manage the Service in a manner designed to protect Our rights and property and to facilitate the proper functioning of the Service.

5.2 We reserve the right to change, modify, or remove the contents of the Service at any time or for any reason at Our sole discretion without notice. However, we have no obligation to update any information on Our Service. We also reserve the right to modify or discontinue all or part of the Service without notice at any time. We will not be liable to You or any third party for any modification, suspension, or discontinuance of the Service.

5.3 We cannot guarantee the Service will be available at all times. We may experience hardware, software, or other problems or need to perform maintenance related to the Service, resulting in interruptions, delays, or errors. We reserve the right to change, revise, update, suspend, discontinue, or otherwise modify the Service at any time or for any reason without notice to You. You agree that we have no liability whatsoever for any loss, damage, or inconvenience caused by Your inability to access or use the Service during any downtime or discontinuance of the Service. Nothing in these Terms and Conditions will be construed to obligate Us to maintain and support the Service or to supply any corrections, updates, or releases in connection therewith.

6. Links to Other Websites

6.1 Our Service may contain links to third-party websites or services that are not owned or controlled by Antengene.

6.2 Antengene has no control over, and assumes no responsibility for, the content, privacy policies, or practices of any third-party websites or services. You further acknowledge and agree that Antengene shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content, goods or services available on or through any such websites or services.

6.3 We strongly advise You to read the terms and conditions and privacy policies of any third-party websites or services that You visit.

7. Termination

7.1 We may terminate or suspend Your access immediately, without prior notice or liability, for any reason whatsoever, including without limitation if You breach these Terms and Conditions.

7.2 Upon termination, Your right to use the Service will cease immediately.

8. Limitation of Liability

8.1 Notwithstanding any damages that You might incur, the entire liability of Antengene and any of its suppliers under any provision of this Terms and Your exclusive remedy for all of the foregoing shall be limited to the amount actually paid by You through the Service or USD100 if You haven't purchased anything through the Service.

8.2 TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL ANTENGENE OR ITS SUPPLIERS BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES WHATSOEVER (INCLUDING, BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, LOSS OF DATA OR OTHER INFORMATION, FOR BUSINESS INTERRUPTION, FOR PERSONAL INJURY, LOSS OF PRIVACY ARISING OUT OF OR IN ANY WAY RELATED TO THE USE OF OR INABILITY TO USE THE SERVICE, THIRD-PARTY SOFTWARE AND/OR THIRD-PARTY HARDWARE USED WITH THE SERVICE, OR OTHERWISE IN CONNECTION WITH ANY PROVISION OF THIS TERMS), EVEN IF ANTENGENE OR ANY SUPPLIER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND EVEN IF THE REMEDY FAILS OF ITS ESSENTIAL PURPOSE.

8.3 YOU AGREE THAT ANY CAUSE OF ACTION OR CLAIM YOU MAY HAVE AGAINST ANTENGENE ARISING OUT OF OR RELATED TO THESE TERMS OR THE SERVICES OR ANY INFORMATION PROVIDED THROUGH THE SERVICES, MUST BE BROUGHT WITHIN ONE (1) YEAR AFTER THE CAUSE OF ACTION OR CLAIM ACCRUES, OR BE PERMANENTLY BARRED.

 

8.4 Some jurisdictions do not allow the exclusion of implied warranties or limitation of liability for incidental or consequential damages, which means that some of the above limitations may not apply. In these jurisdictions, each party's liability will be limited to the greatest extent permitted by law.

9. "AS IS" and "AS AVAILABLE" Disclaimer

9.1 THE SERVICE IS PROVIDED TO YOU "AS IS" AND "AS AVAILABLE" AND WITH ALL FAULTS AND DEFECTS WITHOUT WARRANTY OF ANY KIND. TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW, ANTENGENE, ON ITS OWN BEHALF AND ON BEHALF OF ITS AFFILIATES AND ITS AND THEIR RESPECTIVE LICENSORS AND SERVICE PROVIDERS, EXPRESSLY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SERVICE, INCLUDING ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT, AND WARRANTIES THAT MAY ARISE OUT OF COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OR TRADE PRACTICE. WITHOUT LIMITATION TO THE FOREGOING, ANTENGENE PROVIDES NO WARRANTY OR UNDERTAKING, AND MAKES NO REPRESENTATION OF ANY KIND THAT THE SERVICE WILL MEET YOUR REQUIREMENTS, ACHIEVE ANY INTENDED RESULTS, BE COMPATIBLE OR WORK WITH ANY OTHER SOFTWARE, APPLICATIONS, SYSTEMS OR SERVICES, OPERATE WITHOUT INTERRUPTION, MEET ANY PERFORMANCE OR RELIABILITY STANDARDS OR BE ERROR FREE OR THAT ANY ERRORS OR DEFECTS CAN OR WILL BE CORRECTED.

9.2 WITHOUT LIMITING THE FOREGOING, NEITHER ANTENGENE NOR ANY OF ANTENGENE'S PROVIDER MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED: (I) AS TO THE OPERATION OR AVAILABILITY OF THE SERVICE, OR THE INFORMATION, CONTENT, AND MATERIALS OR PRODUCTS INCLUDED THEREON; (II) THAT THE SERVICE WILL BE UNINTERRUPTED OR ERROR-FREE; (III) AS TO THE ACCURACY, RELIABILITY, OR CURRENCY OF ANY INFORMATION OR CONTENT PROVIDED THROUGH THE SERVICE; OR (IV) THAT THE SERVICE, ITS SERVERS, THE CONTENT, OR E-MAILS SENT FROM OR ON BEHALF OF ANTENGENE ARE FREE OF VIRUSES, SCRIPTS, TROJAN HORSES, WORMS, MALWARE, TIMEBOMBS OR OTHER HARMFUL COMPONENTS.

9.3 Some jurisdictions do not allow the exclusion of certain types of warranties or limitations on applicable statutory rights of a consumer, so some or all of the above exclusions and limitations may not apply to You. But in such a case the exclusions and limitations set forth in this section shall be applied to the greatest extent enforceable under applicable law.

10. Indemnification

You agree to defend, indemnify, and hold Antengene and its Affiliates, licensors, partners, providers, and their respective successors harmless from and against any claims, actions or demands, including, without limitation, reasonable legal and accounting fees, arising or resulting from Your breach of these Terms or Your access to, use or misuse of the Service. Antengene shall provide notice to You of any such claim, suit, or proceeding. Antengene reserves the right to assume the exclusive defense and control of any matter which is subject to indemnification under this section. In such case, You agree to cooperate with any reasonable requests assisting Antengene’s defense of such matter.

11. Governing Law

The laws of the State of New York, excluding its conflicts of law rules, shall govern this Terms and Your use of the Service. Your use of the Application may also be subject to other local, state, national, or international laws.

12. Disputes Resolution

If You have any concern or dispute about the Service, You agree to first try to resolve the dispute informally by contacting Antengene.

13. Compliance

You are solely responsible for ensuring compliance with the laws of Your specific jurisdiction. You expressly agree to comply with any applicable export restrictions under any applicable export control laws and not to export or re-export any part of the Service to countries or persons prohibited under such export control laws. By downloading any content of the Service, You are expressly agreeing that You are not in a country where such export is prohibited or are a person or entity for which such export is prohibited.

14. Translation Interpretation

These Terms and Conditions may have been translated if We have made them available to You on Our Service. You agree that the original English text shall prevail in the case of a dispute.

15. Changes to These Terms and Conditions

15.1 We reserve the right, at Our sole discretion, to modify or replace these Terms at any time. If a revision is material We will make reasonable efforts to provide at least 30 days' notice prior to any new terms taking effect. What constitutes a material change will be determined at Our sole discretion.

15.2 By continuing to access or use Our Service after those revisions become effective, You agree to be bound by the revised terms. If You do not agree to the new terms, in whole or in part, please stop using the Service.

16. Miscellaneous

16.1 If any provision of these Terms is held to be unenforceable or invalid, such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under the applicable law and the remaining provisions will continue in full force and effect.

16.2 Except as provided herein, the failure to exercise a right or to require performance of an obligation under these Terms shall not affect a party's ability to exercise such right or require such performance at any time thereafter nor shall the waiver of a breach constitute a waiver of any subsequent breach.

16.3 Visiting the Service, sending Us emails, and completing online forms constitute electronic communications. You consent to receive electronic communications, and You agree that all agreements, notices, disclosures, and other communications we provide to You electronically, via email and on the Service, satisfy any legal requirement that such communication be in writing.

16.4 These Terms and Conditions and any policies or operating rules posted by Us on the Service or in respect to the Service constitute the entire agreement and understanding between You and Us.

16.5 We may assign any or all of Our rights and obligations to others at any time without notice to You. We shall not be responsible or liable for any loss, damage, delay, or failure to act caused by any cause beyond Our reasonable control.

16.6 There is no joint venture, partnership, employment or agency relationship created between You and Us as a result of these Terms and Conditions or use of the Service.

16.7 You agree that these Terms and Conditions will not be construed against Us by virtue of having drafted them.

17. Contact Us

If You have any questions about these Terms and Conditions, You can contact Us:

· By email: legal@antengene.com